CeleCor Therapeutics: Funding, Investors & Team (Oct 2026)
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and later development of heart failure.
CeleCor Therapeutics has raised $2.7M across 1 funding round on record, the most recent an undisclosed round of $2.7M announced in Mar 2022.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CeleCor Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2022.
CeleCor Therapeutics Funding Rounds
CeleCor Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
CeleCor Therapeutics Funding Compared to Other Biotechnology Startups
CeleCor Therapeutics' latest round of $2.7M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CeleCor Therapeutics in Biotechnology and Del Mar
Companies Similar to CeleCor Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
CeleCor Therapeutics Funding FAQs
What does CeleCor Therapeutics do?
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and later development of heart failure.
How much funding has CeleCor Therapeutics raised?
CeleCor Therapeutics has raised $2.7M across 1 round on record. The most recent is an undisclosed round of $2.7M announced in Mar 2022.
When did CeleCor Therapeutics last raise funding?
CeleCor Therapeutics' most recent funding round on record is an undisclosed round of $2.7M, announced in Mar 2022.
Who is the CEO of CeleCor Therapeutics?
Robert Hillman is listed as CEO at CeleCor Therapeutics.
Where is CeleCor Therapeutics headquartered?
CeleCor Therapeutics is based in Del Mar, California, United States.
How does CeleCor Therapeutics' funding compare to other Biotechnology startups?
CeleCor Therapeutics' latest round of $2.7M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's CeleCor Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CeleCor Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.